AbbVie (NYSE:ABBV – Get Free Report) had its price target upped by stock analysts at Guggenheim from $212.00 to $214.00 in a ...

Among the research grants, Taimalieutu Kiwi Tamasese from The Family Centre has been awarded $80,000 in funding to lead a study on gout within Pasifika communities living in the Wellington and ...

Patients with axSpA and early-stage hypertension face elevated risks for CVEs, likely due to their high inflammatory burden.

UnitedHealth Group, AbbVie, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer to equities in companies that are ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Patients with ankylosing spondylitis and IBD exhibit distinct clinical and radiographic features, compared against those without comorbid IBD.

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...